Stock SEC Filing: Swk Holdings Corp Just Disclosed New Cancer Genetics, Inc Position

Stock SEC Filing: Swk Holdings Corp Just Disclosed New Cancer Genetics, Inc Position

The New Swk Holdings Corp Holding in Cancer Genetics, Inc

Swk Holdings Corp filed with the SEC SC 13G/A form for Cancer Genetics, Inc. The form can be accessed here: 000155278116002091. As reported in Swk Holdings Corp’s form, the filler as of late owns 3.9% or 736,076 shares of the -company.

Cancer Genetics, Inc stake is a new one for the and it was filed because of activity on November 14, 2016. We feel this shows Swk Holdings Corp’s positive view for the stock.

Cancer Genetics, Inc Institutional Sentiment

Latest Security and Exchange filings show 33 investors own Cancer Genetics, Inc. The institutional ownership in Q3 2015 is low, at 30.95% of the outstanding shares. This is increased by 4485028 the total institutional shares. 5847388 were the shares owned by these institutional investors. In total 5 funds opened new Cancer Genetics, Inc stakes, 13 increased stakes. There were 5 that closed positions and 6 reduced them.

Philip Hempleman Ardsley Advisory Partners is an institutional investor bullish on Cancer Genetics, Inc, owning 15000 shares as of Q3 2015 for 0.03% of its portfolio. Sterneck Capital Management Llc owns 20030 shares or 0.10% of its portfolio. PA Millrace Asset Group Inc have 1.67% of their stock portfolio for 198774 shares. Further, Diker Management Llc reported stake worth 0.05% of its US stock portfolio. The NY Domini Social Investments Llc owns 30048 shares. Cancer Genetics, Inc is 3.84% of the manager’s US portfolio.

Business Profile

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.5 in Q2 2016. Its up 0.87, from 0.63 in 2016Q1. The ratio improved, as 6 funds sold all Cancer Genetics Inc shares owned while 4 reduced positions. 6 funds bought stakes while 9 increased positions. They now own 1.58 million shares or 24.74% more from 1.27 million shares in 2016Q1.

Moreover, Goldman Sachs Incorporated has 0% invested in Cancer Genetics Inc (NASDAQ:CGIX) for 11,523 shares. The Pennsylvania-based Pnc Fin Gp Incorporated has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Diker Ltd has 0.02% invested in the company for 29,815 shares. Morgan Stanley accumulated 20,542 shares or 0% of the stock. Barclays Public Limited Liability has 454 shares for 0% of their US portfolio. Moreover, Blackrock Institutional Trust Na has 0% invested in Cancer Genetics Inc (NASDAQ:CGIX) for 12,424 shares. Vanguard Incorporated last reported 326,966 shares in the company. Brown Advisory reported 18,000 shares or 0% of all its holdings. Geode Capital Ltd Liability Corp has 41,243 shares for 0% of their US portfolio. Perkins Capital Mngmt owns 581,200 shares or 1.33% of their US portfolio. Eagle Glob Advisors Ltd Liability holds 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 84,320 shares. Blackrock Fund Advsr has 0% invested in the company for 36,862 shares. The Georgia-based Advisory Services Ntwk Lc has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Tocqueville Asset Mgmt Lp last reported 0% of its portfolio in the stock. Beck Mack Oliver Limited Liability holds 0% or 18,225 shares in its portfolio.

Insider Transactions: Since August 12, 2016, the stock had 2 insider purchases, and 0 sales for $421,491 net activity. $318,288 worth of Cancer Genetics Inc (NASDAQ:CGIX) shares were bought by PAPPAJOHN JOHN.

The stock increased 6.67% or $0.1 on November 11, hitting $1.6. Cancer Genetics Inc (NASDAQ:CGIX) has declined 36.51% since April 12, 2016 and is downtrending. It has underperformed by 41.49% the S&P500.

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products, and molecular markers. The company has a market cap of $32.20 million. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. It has a range of disease-focused oncology testing portfolio.

Cancer Genetics Inc (NASDAQ:CGIX) Ratings Coverage

Out of 3 analysts covering Cancer Genetics (NASDAQ:CGIX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $8 is the highest target while $6 is the lowest. The $7 average target is 337.50% above today’s ($1.6) stock price. Cancer Genetics has been the topic of 3 analyst reports since March 11, 2016 according to StockzIntelligence Inc. As per Monday, September 26, the company rating was initiated by Rodman & Renshaw. On Tuesday, March 15 the stock rating was maintained by Aegis Capital with “Buy”. The firm has “Neutral” rating given on Friday, March 11 by Janney Capital.

More notable recent Cancer Genetics Inc (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics, Inc. Launches Focus::Renalâ„¢, a Unique, Comprehensive and …” on November 02, 2016, also Globenewswire.com with their article: “Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock …” published on October 14, 2016, Nasdaq.com published: “Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year …” on November 10, 2016. More interesting news about Cancer Genetics Inc (NASDAQ:CGIX) were released by: Globenewswire.com and their article: “Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker …” published on July 18, 2016 as well as Seekingalpha.com‘s news article titled: “Cancer Genetics: ‘Warrant,’ You Are Under Arrest” with publication date: July 15, 2016.

According to Zacks Investment Research, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.”

CGIX Company Profile

Cancer Genetics, Inc., incorporated on April 8, 1999, is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products and molecular markers. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. The Company’s molecular- and biomarker diagnostic services are for three main sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. The Company’s services include clinical services, biopharma services and discovery services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment